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Abstract
Background: Traditionally IFN/STAT1 signaling is connected with an anti-viral response and pro-apoptotic tumor-
suppressor functions. Emerging functions of a constitutively activated IFN/STAT1 pathway suggest an association with an
aggressive tumor phenotype. We hypothesized that tumor clones that constitutively overexpress this pathway are
preferentially selected by the host microenvironment due to a resistance to STAT1-dependent cytotoxicity and demonstrate
increased metastatic ability combined with increased resistance to genotoxic stress.
Methodology/Principal Findings: Here we report that clones of B16F1 tumors grown in the lungs of syngeneic C57BL/6
mice demonstrate variable transcriptional levels of IFN/STAT1 pathway expression. Tumor cells that constitutively
overexpress the IFN/STAT1 pathway (STAT1
H genotype) are selected by the lung microenvironment. STAT1
H tumor cells also
demonstrate resistance to IFN-gamma (IFNc), ionizing radiation (IR), and doxorubicin relative to parental B16F1 and low
expressors of the IFN/STAT1 pathway (STAT1
L genotype). Stable knockdown of STAT1 reversed the aggressive phenotype
and decreased both lung colonization and resistance to genotoxic stress.
Conclusions: Our results identify a pathway activated by tumor-stromal interactions thereby selecting for pro-metastatic
and therapy-resistant tumor clones. New therapies targeted against the IFN/STAT1 signaling pathway may provide an
effective strategy to treat or sensitize aggressive tumor clones to conventional cancer therapies and potentially prevent
distant organ colonization.
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Introduction
Metastasis is the primary cause of death in most cancer patients.
The treatment of patients with metastatic disease in adult solid
tumors remains largely palliative. The ineffectiveness of standard
cancer therapies against metastatic disease is reflected by the marked
disparity in survival from the time of diagnosis for localized versus
distant disease [1]. This disparity is hypothesized to be due to a
greater disease burden in patients with metastatic disease and the
intrinsic resistance of metastatic disease to most cancer therapies.
Metastasis resistance to conventional therapy is believed to be due to
the multiple genetically unstable cell populations found within
tumors [2]. Though there are many investigations into the
mechanisms of metastasis, little is known regarding the mechanisms
of metastatic progression that contribute to therapy resistance.
One key selection pressure shaping tumor cell evolution is the
tumor microenvironment, which includes tumor cells, host stromal
cells, extracellular matrix, and cells of the immune system. One
component of the interaction between the tumor and the
microenvironment is mediated by the immune system via
‘‘immunoediting’’ [3]. Immunoediting is proposed to be the
process by which the immune system drives tumor cell selection
towards an immune-resistant phenotype [3,4], including resistance
to the multiple host-secreted cytokines.
A key cytokine in tumor-suppressive networks is IFN-gamma
(IFNc) [5]. IFNc mediates its effect on cells by interacting with
type II IFN receptors (IFNGR1 and IFNGR2). Upon receptor
binding, IFNc activates the JAK/STAT1 dependent signaling
pathway.
STAT1, the first described member of the STAT transcription
factor family [6], is the master transcription factor for IFN-related
intracellular signaling and therefore tumor suppression related to
IFNs. STAT1 is phosphorylated by JAK1/2 kinases at the Tyr701
position and then translocates to the nucleus where it binds to
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activating several hundred genes. These interferon-stimulated
genes comprise the IFN/STAT1 signaling pathway [7,8].
Therefore, the IFN/STAT1 pathway represents a signaling
pathway that mediates crosstalk between the host microenviron-
mental components and the tumor cells.
Genes activated by STAT1 determine many of the functions
related to the IFN/STAT1 pathway. Previous studies demon-
strated that STAT1 controls anti-tumorigenic effects in part by up-
regulation of caspases 1, 2, 3, 7, and 8 [9–12], cyclin-dependent
kinase inhibitor 1A (CDKN1A) [13], the IFN-regulatory Factor 1
(IRF1)/p53 pathway [14], and down-regulation of the BCL2 (B-
cell CLL/Lymphoma 2) family [15]. STAT1 also is involved in
anti-angiogenic mechanisms, partially through the induction of
IFNc-induced protein 10 (IP10 or CXCL10), thereby suppressing
tumorigenesis [16].
In contrast, emerging data reveal that in certain cellular
contexts the IFN/STAT1 pathway may mediate tumor cell
growth. Previously, we demonstrated that a radioresistant tumor
(Nu61), selected against fractionated ionizing radiation (IR) from a
radiosensitive parental tumor SCC61, constitutively overexpresses
the IFN/STAT1 pathway [17]. The nu61 radioresistant tumor
and corresponding cell lines were also found to be resistant to IFN-
mediated cytotoxicity [18]. A subsequent study demonstrated that
selection of SCC61 against IFN-alpha (IFNa) and IFNc produced
a similar IR- and IFN-resistant phenotype overexpressing the
IFN/STAT1 pathway [18]. Thus, we concluded that resistance to
IR and IFNs is associated with constitutive overexpression of the
IFN/STAT1 pathway. Consistent with our observations are
recent reports indicating that constitutive overexpression of
STAT1 and STAT1-dependent genes is associated with protection
of tumor cells from genotoxic stress following treatment with
fludarabine [19], doxorubicin (Dox) [20], cisplatin [21], and the
combination of IR and Dox [22,23]. Overexpression of the IFN/
STAT1 pathway is also associated with poor prognosis in different
types of cancer and may have predictive value in breast cancer
patients selected for the adjuvant chemotherapy [24,25].
Based on these findings, we hypothesized that in vivo selection of
developing tumor clones would be associated with the ability of
tumor cells to overexpress the IFN/STAT1 pathway while
resisting IFNc-mediated cytotoxicity. To test this hypothesis we
used the syngeneic B16Fl mouse melanoma lung colonization
model as a surrogate for metastatic propensity. This model was
developed and described in detail by Fidler and colleagues [26–28]
(see [2] for review). We investigated whether differences in
phenotype between parental B16F1 and its derivatives passed
through the lungs are related to IFNc-resistance, IFN/STAT1
pathway overexpression, and resistance to cytotoxic therapy
including IR and chemotherapy.
Here we report that tumor cells that constitutively overexpress
the IFN/STAT1 pathway, and are thus resistant to the cytotoxic
effects of this pathway, are preferentially selected for colonization
by the lung microenvironment. Clones overexpressing this
pathway produce a greater number of lung colonies compared
to clones that do not constitutively overexpress the IFN/STAT1
pathway. We demonstrate the pre-existence of clones in the B16F1
tumor cell population that overexpress the IFN/STAT1 pathway.
These clones are also resistant to IR and Dox. Suppression of
STAT1 by stable knockdown using small hairpin RNA (shRNA)
leads to a reversion of the phenotype, decreased ability to form
lung colonies and decreased resistance to genotoxic stress. These
data provide a mechanistic explanation for the STAT1-depen-
dence of pro-metastatic and therapy-resistant tumor clones. We
propose that overexpression of the IFN/STAT1 pathway
contributes to therapy resistance and metastatic propensity leading
to the poor response to traditional cancer therapy observed in
patients with metastatic disease.
Results
Efficiency of lung colonization is accompanied by
development of resistance to IFNc
We examined lung colonization following injection of B16F1
melanoma cells in IFNc
2/2 mice compared with C57BL/6
controls. After injection of 5610
4 B16F1 cells, 7/9 IFNc
2/2 mice
developed lung colonies (mean number of lung colonies per
mouse=37.6625.6). C57BL/6 mice developed significantly fewer
lung colonies (7/16, number of lung colonies per
mouse=2.161.2; Student’s two-tailed t-test; p=0.0034;
Figure 1A-B). These observations are consistent with prior
reports demonstrating that IFNc
2/2 mice develop a greater
number of lung colonies than wild type mice [5,29,30]. Passage of
B16F1 cells through the lungs led to the formation of the highly
metastatic daughter tumor B16F10 [26]. We suggested that such
passages should lead to an increase in resistance to IFNc and we
compared the sensitivity of B16F1 and B16F10 cells to IFNc with
a MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) assay. We found that B16F10
cells were significantly more resistant to IFNc that B16F1 cells
(Student’s two-tailed t-test; p=1.07610
25; Figure 1C). Taken
together these results confirm the importance of IFNc in
suppressing B16F1 lung colonization and suggest that lung
colonization is associated with resistance to IFNc.
Quantification of IFN/STAT1 pathway expression and
definition of STAT1
H and STAT1
L genotype
The IFN/STAT1 pathway mediates transduction of IFN signals
into the nuclei of target cells. This transduction involves activation
of Type I and Type II IFN receptors, receptor-associated JAK/
TYK (tyrosine kinase) kinases and eventually activation and
nuclear translocation of STAT1. IFN-mediated STAT1 transcrip-
tional induction results in the transcription of several hundred
genes designated the Interferon-Stimulated Genes (ISG; see
[8,31,32] for reviews). To define a cut-off expression level to
delineate high and low expressors of the IFN/STAT1 pathway we
developed a method for rapid and efficient screening of cell lines
and tumor clones. Prior studies demonstrate that activation of the
IFN/STAT1 pathway can be measured by PCR-based quantifi-
cation of gene expression using marker ISGs [33–36].
We selected five genes – STAT1, IFIT1 (interferon-induced
protein with tetratricopeptide repeats 1), IFIT3 (interferon-
induced protein with tetratricopeptide repeats 3), IFITM1
(interferon induced transmembrane protein 1), and MX1 (Myxo-
virus resistance protein 1) – to comprise our IFN/STAT1 pathway
marker gene set based on following criteria. First, the literature
confirms that these five genes are PCR–detectable markers of the
IFN/STAT1 pathway. Specifically data have been published for
STAT1 [34], MX1 [34,35], IFITM1 [37], IFIT1, and IFIT3
[36,37]. Secondly, we calculated the correlation between our DNA
array data from our originally described interferon-related gene
signature [17] with QRT-PCR (quantitative real time PCR)
amplification data of 19 different ISGs included in this signature.
Our results demonstrate that the five marker genes selected for the
current study are located within the 95% confidence interval
(Pearson’s R=0.803, p,0.001, Figure S1). Third, we tested
these five IFN/STAT1 pathway marker genes in multiple cell lines
and xenografts. We found that these five genes were amplified in
response to IFNs and/or IR in 3 of 3 cell lines and 7 of 8
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derived seven-gene TSP (top scoring pair) classifier related to ISGs
that is associated with poor prognosis and chemo- and radio-
resistance in tumors [25]. Four out of seven TSP genes (STAT1,
IFIT1, IFIT3 and MX1) overlap with our five-gene IFN/STAT1-
pathway marker set (see above). Expression of each marker gene
was normalized to B16F1 and the expression of all five genes was
combined to generate our IFN/STAT1 expression score [33,38].
This score was calculated as an average of the log2-transformed
expression value for each of the five marker genes (see Methods for
details) and was used to estimate the IFN/STAT1 pathway
expression level in experimental cell lines and tumor clones.
To test whether the expression score, as defined above,
discriminates IFN/STAT1 pathway high (STAT
H) and low
(STAT
L) expressors relative to B16F1 baseline, we performed
QRT-PCR to profile eight cell lines from the P1 passage (B16F1
passed through the lungs of wild type C57BL/6 mice; Figure 1D
and Figure S2). Three of these cell lines (P1M3D, P1M3E, and
P1M7) demonstrated an up-regulation of the five-gene marker set
relative to B16F1 and had positive IFN/STAT1 pathway
expression scores (0.81, 1.21 and 0.89; Figure 1D). These cell
lines were defined as overexpressors of IFN/STAT1 pathway
(STAT1
H; Figure 1D). The other five cell lines (P1M1, P1M4B,
P1M4C, P1M5B and P1M8D) did not change or exhibited a
down-regulation of the five-gene marker set relative to B16F1.
These cell lines showed negative IFN/STAT1 pathway expression
scores ranging from 20.13 to 20.9 and were defined as low
expressors (STAT1
L; Figure 1D). The difference between scores
for STAT1
H and STAT1
L cell lines was significant (Student’s two-
tailed t-test; p=0.0007; Figure 1D). We set the threshold
expression score separating STAT1
H and STAT1
L genotypes at
0.8, which approximates the lowest score of the three STAT1
H P1
cell lines (P1M3D cell line, Figure 1D). Subsequently, cell lines
were designated STAT1
H if their IFN/STAT1 pathway expression
score was$0.8 and STAT1
L if their IFN/STAT1 pathway
expression score was ,0.8.
Figure 1. IFN/STAT1 signaling differs between tumor cell lines and is required for suppression of lung colonization. (A) Number of
mice developing lung colonies and total number of lung colonies per mouse in C57BL/6 wild type and IFNc
2/2 mice after intravenous injection of
B16F1 tumor cells (horizontal line represents mean). (B) Images of wild type and IFNc
2/2 explanted lungs demonstrate marked difference in number
of lung colonies. (C) Differential response to IFNc in vitro between B16F1 (parental) and B16F10 (passaged, more aggressive) cell lines (mean6SD). (D)
Variable fold-induction of IFN/STAT1 marker genes for eight cultured cell lines from P1 passage B16F1 lung colonies in C57BL/6 mice (numbers
represent expression scores).
doi:10.1371/journal.pone.0005821.g001
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associated with B16 melanoma lung colonization
We tested the hypothesis that tumor clones overexpressing the
IFN/STAT1 pathway (STAT1
H) exhibit an increase in lung
colonization compared to cells that do not overexpress this
pathway (STAT1
L). Three P1 STAT1
H clones (P1M3D, P1M3E,
and P1M7) were pooled as were three P1 STAT1
L clones (P1M4B,
P1M4C, and P1M5B) and then injected into mice. In the P2 group
of mice injected with the P1 STAT1
L clones, 7 of 10 animals
developed 2.862.5 lung colonies per animal which is equivalent to
the number of lung colonies for parental B16F1 (2.161.2; 7/16
mice; Figure 2). By contrast, P2 mice injected with P1 STAT1
H
clones showed a marked increase in both the frequency of colony
formation (16/20 mice; Fisher’s exact test; p=0.023) and the
number of lung colonies per mouse (31.0631.8; Student’s two-
tailed t-test; p=2.4x10
24; Figure 2). These data indicate that the
expression level of the IFN/STAT1 pathway affects the ability of
B16F1 cells to colonize the lungs following IV injection.
Propagation of the STAT1
H genotype in tumor passages
The lung colonies produced by P1 STAT1
H and P1 STAT1
L cell
lines were then used to generate a P2 panel of cell lines (Figure 2
and Figure S2). Nine cell lines were isolated from P2 STAT1
L
colonies and 25 cell lines from P2 STAT1
H colonies (Figure 3A).
The two cell lines from the P2
H panel with the highest STAT1
expression score, P2M3C (expression score=2.36) and P2M5A
(expression score=2.87; Figure 3A) were pooled and injected
intravenously into mice. These two pooled cell lines produced lung
colonies in 90% (9/10) of mice with 37.9618.7 colonies per mouse
(p=0.0046 compared with P2
L; Figure 2). Lung colonies derived
from this third in vivo passage are indicated as P3
H and 14 cell lines
were cultured from these lung colonies (Figure 3A). All cell lines
derived from in vivo passages are summarized in Table S1.
The mean STAT1 expression score shows a progressive increase
from the P1 to the P3 passage with a significant difference between
the P1 and P3 panels of cell lines (Student’s two-tailed t-test;
p=0.006; Figure 3C). In the P1 cell lines, 3/8 (37.5%) of the cell
lines exhibited a STAT1 expression score $0.8, classifying them as
STAT1
H. Of the P2
L cell lines only 2/9 (22.2%) represented
STAT1
H genotype while in the P2
H cell lines 11/25 (44%)
belonged to STAT1
H genotype. In the P3 cell lines 9/13 (69.2%)
exhibited the STAT1
H genotype. Thus, an increase in the
frequency of the STAT1
H cell lines and an increase in the mean
level of STAT1 expression scores occurs during the progression
Figure 2. Passage of B16 cell lines based on IFN/STAT1 pathway expression level coincides with an increase in number of lung
colonies. (A) Number of lung colonies per mouse after intravenous injection of 5610
4 tumor cells (horizontal line=mean number of lung colonies
per mouse). (B) Representative images of lungs explanted from mice intravenously injected with 5610
4 P2
L,P 2
H,o rP 3
H tumor cells, respectively.
doi:10.1371/journal.pone.0005821.g002
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lung colony forming efficiency is significantly associated with
expression levels of the IFN/STAT1 pathway.
Tumor clones overexpressing IFN/STAT1 pathway pre-
exist in B16F1 population
It was previously demonstrated that B16F1 cells have variable
abilities to colonize the lungs due to preexisting heterogeneity of
the tumor cell population [39]. It was suggested that the observed
variability in B16F1 lung colonization proficiency might be
connected with pathways that confer an increased capacity to
colonize the lungs of C57BL/6 mice. In the current report we
show that the ability to colonize the lungs is associated with
constitutive overexpression of the IFN/STAT1 pathway (STAT1
H
genotype). We therefore hypothesized that the B16F1 cell
population may contain pre-existent cells with a STAT1
H
genotype. To test this hypothesis we cloned B16F1 cells (see
Methods) and investigated the expression levels of the IFN/
STAT1 pathway in the progeny of monoclones. Five of 20 tested
monoclones were STAT1
H, and therefore overexpressed the IFN/
STAT1 pathway (Student’s two-tailed t-test; p=5.33610
25;
Figure 4A).
We further compared in vitro monoclones to in vivo lung colonies
with respect to expression of the IFN/STAT1 pathway. Eight lung
colonies profiled in vivo demonstrated up-regulation of the IFN/
STAT1 pathway from 60- to 120-fold relative to basal B16F1 in
vitro depending on the marker genes (Figure 4B). On the
contrary, STAT1
H cell lines from the P1 panel (Figure 1D) and
B16F1 monoclones (Figure 4A) exhibited up-regulation of the
IFN/STAT1 pathway only 2 to 3-fold relative to baseline. These
data indicate that the lung microenvironment uniformly up-
regulates the IFN/STAT1 pathway in lung colonies.
To confirm that the observed pathway up-regulation was
directly related to factors from the lung microenvironment, B16F1
was co-cultured with explanted lung tissue (see Methods and
[40,41]). B16F1 co-culture with explanted lung tissue led to a
marked (4 to 37 fold) up-regulation of the IFN/STAT1 pathway
compared with B16F1/B16F1 mono-culture (Student’s two-tailed
t-test; p =0.0174; Figure 4C). It is noteworthy that IFN/STAT1
pathway up-regulation in co-culture is similar to the difference in
expression between B16F1 monoclones in vitro and P1 lung
colonies in vivo (Figure 4B). Two important conclusions were
made from these experiments. First, the population of B16F1 cells
is heterogeneous with respect to the IFN/STAT1 pathway
expression and contains pre-existing STAT1
H variants prior to in
vivo passage. According to our observations, these cells are likely
resistant to IFNc cytotoxicity ([17,18] and Figure 5). The second
conclusion is that the lung microenvironment significantly up-
regulates the IFN/STAT1 pathway in tumor clones, which may
create a selection pressure and provide a survival advantage to the
preexisting STAT1
H clones that are inherently resistant to this
cytotoxic microenvironment.
Figure 3. IFN/STAT1 pathway expression level and frequency of STAT1
H clones increases with passage number. (A) Individual gene
heat map and (B) STAT1 expression score of IFN/STAT1 pathway based on QRT-PCR expression levels for P1, P2
L,P 2
H, and P3
H cell lines. (C) Mean IFN/
STAT1 pathway expression score for P1, P2
L,P 2
H, and P3
H cell lines (mean6SEM). See Table S1 for a description of cell lines and raw data.
doi:10.1371/journal.pone.0005821.g003
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H tumor clones are resistant to IFNc
To test the hypothesis that overexpression of the IFN/STAT1
pathway in B16F1 cells correlates with IFNc resistance (see
above), STAT1
H and STAT1
L cell lines from all three passages
were challenged with 10 ng/mL of IFNc and viability assayed
using MTS (see Methods). The mean viability of STAT1
H clones
was 16.0266.7%, while that of STAT1
L clones was 1.6666.21%
(Student’s two-tailed t-test; p=0.00001; Figure 5A; Table S2).
Furthermore, IFNc-resistant cell lines co-clustered with STAT1
H
cell lines (Figure 5B). Lastly, there was a strong correlation
between STAT1 expression score and resistance to IFNc
(Pearson’s R=0.717; p=0.0002; Figure 5C). These results
demonstrate that STAT1
H tumor clones are more resistant to
IFNc compared with STAT1
L tumor clones. Taken together with
the data presented above, these findings indicate that overex-
pression of the IFN/STAT1 pathway is associated with
resistance to IFNc.
Resistance to IFNc in STAT1
H tumor clones is also
associated with resistance to ionizing radiation
We previously reported that selection of the radioresistant
tumor nu61 by in vivo fractionated IR was accompanied by
overexpression of the IFN/STAT1 pathway and combined
resistance to IR, IFNa, and IFNc [17,18]. We also showed that
selection of the sensitive parental tumor SCC61 against IFNa or
IFNc led to constitutive overexpression of the IFN/STAT1
Figure 4. STAT1
H variants pre-exist in the B16F1 population and the lung microenvironment stimulates the IFN/STAT1 pathway. (A)
STAT1
H variants pre-exist in a B16F1 population (red line represents expression score cutoff of 0.8 for STAT1
H or STAT1
L). (B) In vivo lung colonies have
a markedly increased IFN/STAT1 pathway expression level compared with in vitro monoclones. (C) Induction of IFN/STAT1 pathway after in vitro co-
culture of B16F1 with explanted lung tissue demonstrates a significant increase relative to B16F1 monocultures (p=0.0174; mean6SD).
doi:10.1371/journal.pone.0005821.g004
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hypothesized that STAT1
H B16 clones having an increased
propensity to colonize the lungs and demonstrating resistance to
IFNc, would also grow more rapidly and be resistant to IR.
To test this hypothesis, we compared two cell lines derived from
second generation lung colonies (P2) in which P2M3C was derived
from pooled P1 STAT1
H cell lines (P2
H) and P2M6B was derived
from pooled P1 STAT1
L cell lines (P2
L)( Figure 3 and Figure
S2). Also, P2M3C (P2
H) was previously shown to be resistant to
IFNc, while P2M6B (P2
L) was sensitive to IFNc (Figure 5 and
Table S2). The parental B16F1 cell line was used as a control.
Experiments were performed in vivo using hind limb injections of
tumor cells into C57BL/6 mice as previously described [42] (see
Methods). At day 13 after hind limb injection, the relative volume
[43] of untreated P2M3C (STAT1
H) tumors was 19.061.97 while
that of P2M6B (STAT1
L) was 12.061.92 (1.6-fold difference;
Student’s two-tailed t-test; p=0.035). These data demonstrate that
P2M3C (STAT1
H) grew significantly faster compared to P2M6B
(STAT1
L) and B16F1 (Figure 6).
Tumors irradiated with 20 Gy demonstrated a similar trend. At
day 21 after IR the relative tumor volume of irradiated P2M3C
was 3.9 times larger (22.766.67) than the relative volume of
P2M6B (5.861.78; Student’s two-tailed t-test; p=0.04; Figure 6).
Thus, after a single dose of 20 Gy, the differences in relative
volumes increased between tumors derived from STAT1
H and
STAT1
L cell lines. Therefore, consistent with our previous
Figure 5. Resistance to IFNc correlates with expression of IFN/STAT1 pathway.( A) Survival of STAT1
H and STAT1
L cell lines relative to
control B16F1 after treatment with 10 ng/ml of IFNc (horizontal line represents mean value). (B) Gene expression heat map of STAT1
H and STAT1
L cell
lines used for IFNc resistance experiment. (C) Correlation between IFN/STAT1 pathway expression level and resistance to IFNc (see Table S2).
doi:10.1371/journal.pone.0005821.g005
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pathway are resistant to both IR and IFNc.
STAT1
H clones demonstrate resistance to Doxorubicin
We previously demonstrated that STAT1
H tumors overex-
pressing the IFN/STAT1 pathway are resistant to Dox
treatment and that constitutive expression of this pathway is
predictive for response to adjuvant chemotherapy in patients
with breast cancer [18,25]. We hypothesized that the resistance
of STAT1
H tumor clones to Dox is linked to an impaired
apoptotic response similar to our recent data for nu61 and
SCC61 cell lines [18,44]. To test this, we chose six cell lines,
three of which were STAT1
H (P3M2A, P2M3C and P3M5A;
Figure 3A) and three cell lines that were STAT1
L (P2M3,
P2M6B and P2M5B; Figure 3A). Cells were treated with Dox
for 24 hours and the apoptotic response was measured by
activation of caspases 3/7 (see Methods). Dox activated caspases
3/7 in all the tested cell lines, but the three STAT1
L cell lines had
a significantly higher apoptotic response compared to STAT1
H
cell lines (Figure 7). The mean level of apoptosis induction in
STAT1
L cells was 34.165.7 fold, while in STAT1
H cells it was
18.361.9 fold relative to untreated cells (Student’s two-tailed t-
test, p=0.013). It is noteworthy that the two STAT1
L cell lines
with the maximal apoptotic response (P2M6B and P2M5B) were
also sensitive to IFNc,w h i l et h et w oSTAT1
H cell lines with the
minimal apoptotic response (P3M2A and P2M3C) were resistant
to IFNc (Figures 3A, 5 and Table S2). P3M5A and P2M3
had intermediate levels of Dox-induced apoptosis and were
characterized by intermediate levels of resistance to IFNc
(Figure 5 and Table S2). These results support two
conclusions. First, the STAT1-dependent development of tumor
clones with an increased propensity for lung colonization and
resistance to IFNc is associated with the development of
resistance to Dox. Second, this resistance is linked to impaired
apoptotic response through suppression of caspase 3/7 activa-
tion, which is consistent with our previous reports [18,44].
Development of tumor clones proficient in lung
colonization and resistant to genotoxic stress is
mechanistically connected to STAT1
Previously, we showed that stable knockdown of STAT1 in IR-
resistant and IFNa/IFNc-resistant tumor cells led to radiosensi-
tization [18], suggesting that STAT1 is one important mediator in
the IR-resistant tumor phenotype. We used the same approach to
test the hypothesis that STAT1 mediates the development of an
aggressive pro-lung colonization phenotype as described here. We
selected the cell line with the highest STAT1 score from the P2
STAT1
H panel (P2M5A) (Figure 3A and Table S1). Stable
STAT1 knockdowns of this cell line were generated using shRNA
(see Methods). For in vivo colonization experiments, we tested
P2M5A-24 and P2M5A-26 cell lines as they had maximal
suppression of STAT1 with 6- and 12-fold suppression, respec-
tively, as measured by QRT-PCR (results not shown).
Lungs were explanted and colonies counted at two and three
weeks after IV injection. P2M5A cells transfected with the control
vector produced lung metastases in 100% of mice at two and three
weeks with the mean number of lung metastases per mouse
94.366.5 at two weeks and 102639.6 at three weeks (Figure 8A).
Six-fold suppression of STAT1 with shRNA 24 led to a 4–5 fold
suppression in lung colonization (Student’s two-tailed t-test;
p=0.003), although 100% of mice still developed lung metastases
at two and three weeks. However, 12-fold suppression of STAT1
with shRNA 26 corresponded to a 56-fold suppression (Student’s
two-tailed t-test; p=0.0002) in lung colonization with a decrease
in the incidence of lung metastases from 100% to 11% at two
weeks (Fisher’s exact test; p=1.7610
25) and 60% to 100% at
three weeks (Fisher’s exact test; p=0.018; Figure 8A-B). These
data demonstrate that STAT1 signaling is a key factor controlling
Figure 6. STAT1
H tumors are resistant to IR. STAT1
H (P2M3C)
tumors grow faster and are resistant to IR compared with STAT1
L
(P2M6B) and B16F1 parental tumors. (Vn/Vo=relative change in volume,
day 0=IR (20Gy), mean6SEM)
doi:10.1371/journal.pone.0005821.g006
Figure 7. STAT1
H cell lines are resistant to doxorubicin-induced
apoptosis. Caspase 3/7 activation as a measure of apoptosis in cells
exposed to doxorubicin (1 mM) for 24 hours (mean6SD, horizontal line
represents mean for STAT1
H and STAT1
L groups). Data are presented as
fold-induction relative to control (un-treated) cells.
doi:10.1371/journal.pone.0005821.g007
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that suppression of STAT1 can convert the tumor phenotype to
poor lung colonizers.
Considering our previous observations of a relationship between
expressionoftheIFN/STAT1pathway,colonizationpropensity,and
resistance to genotoxic stress, we investigated the effects of STAT1
knockdown in P2M5A (IFN/STAT1 pathway overexpressing) cells
on the response to treatment with Dox. Knockdown of STAT1 by
both shRNA constructs (24 and 26) led to a significant activation of
apoptotic response following treatment with Dox compared with the
control-vector transfected cell line as measured by activation of
caspases 3 and 7 (Student’s two-tailed t-test; p=7.3610
-5;
Figure 8C). These results are consistent with our previous finding
that STAT1 knockdown causes tumor sensitization to genotoxic stress
Figure 8. Knockdown of STAT1 using shRNA mitigates aggressive phenotype and restores sensitivity to doxorubicin.( A) Number of
lung colonies per mouse produced by control-transfected (P2M5A-MT) and shRNA knockdown (P2M5A-24 and P2M5A-26) cell lines. Shown are data
for 2 (white bars) and 3 (gray bars) weeks after IV injection (mean6SEM). (B) Representative images of lungs, colonized by respective cell lines. (C)
Caspase 3/7 activation as a measure of apoptosis in control (P2M5A-MT) and shRNA knockdown (P2M5A-24 and P2M5A-26) cells exposed to
doxorubicin (1 mM) for 24 hours.
doi:10.1371/journal.pone.0005821.g008
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important role in the lung colonization ability of B16F1 clones and
derivatives and that STAT1 provides a molecular link between
colonization propensity and resistance of metastatic tumor clones to
cytotoxic stimuli.
Discussion
The relationship between overexpression of the IFN/STAT1
pathway and malignancy was initially described for breast
tumors [45,46]. Subsequently, Chung et al. compared gene
expression patterns in lung and breast cancers and found two
common functional clusters – a proliferation cluster and an IFN/
STAT1 cluster [47]. However, the biological significance of
overexpression of the IFN/STAT1 pathway remained unclear.
We previously demonstrated an association between an IR-
resistant phenotype and overexpression of IFN/STAT1 pathway
in head and neck cancer cell lines [17]. Furthermore, stable
transfection of STAT1 in the radiosensitive SCC61 cell line led to
the formation of an IR- and IFN-resistant phenotype, thus
confirming that constitutive overexpression of STAT1 conferred
resistance to genotoxic stress. We then demonstrated that
selection of SCC61 against IFNc and IFNa led to a similar
IR- and IFN-resistant phenotype [18].
These observations lead us to hypothesize that the development
of tumor clones overexpressing the IFN/STAT1 pathway is
associated with selection against IFNs, and perhaps other STAT1-
activating ligands, secreted by the host microenvironment leading
to the selection of cells resistant to the cytotoxic effects of transient
STAT1 activation. This resistance is also associated with resistance
to IR and chemotherapy, a characteristic of aggressive tumors
[18,25]. Indeed, in an ex vivo co-culture model it was demonstrated
that stromal fibroblasts can secrete IFNs, activating the IFN/
STAT1 pathway in breast cancer cells, and that this pathway is
associated with poor prognosis in patients with breast cancer due
to the development of metastases [48]. Our current data are
consistent with these observations [25].
Our two most important findings reported here are that we
demonstrate using an in vivo syngeneic model that the development
of tumor clones within the host microenvironment leads to the
preferential selection of clones constitutively overexpressing the
IFN/STAT1 pathway with an associated improved ability to
colonize the lung microenvironment. Second, we confirmed that
these clones are resistant to genotoxic insult delivered by cytotoxic
cytokines, IR, and chemotherapy. These findings raise questions
about the potential role of the IFN/STAT1 pathway in metastasis
development.
Metastasis emerges as a result of genetic and epigenetic
evolution driven by selection pressures created by the host
microenvironment and within the tumor itself. A minority of cells
from the heterogeneous tumor cell population survive these
selection pressures (see [49] for review). The majority of tumor
cells are eliminated during the metastatic cascade through multiple
microenvironmental stresses including tissue barriers, regulation of
nutrients and energy supplies through angiogenesis and hypoxia,
interactions with the extracellular matrix, shear stresses within the
bloodstream, networks of the cytotoxic cytokines, and tumor
surveillance by the immune system (see [49–51] for reviews). As a
result, only tumor cells with intrinsic properties that provide
advantages in this multi-step selection process will survive and
colonize distant sites. In this regard, we asked whether overex-
pression of the IFN/STAT1 pathway provides such a selective
advantage to tumor cells, thereby leading to improved lung
colonization.
To investigate these questions we used a syngeneic B16 mouse
melanoma lung colonization model [26–28] (see [2] for review).
Given the above mentioned data regarding the complexity and
multi-stage nature of the metastatic process, we used the total
number of surface lung colonies formed by the parental B16F1
and its derivatives as the endpoint to measure metastatic
propensity. The individual lung colonies, which are believed to
be the progeny of a single lung colonizing tumor cell [52], were
used to establish cell lines in which we examined levels of
expression of the IFN/STAT1 pathway. Also, given that IFN/
STAT1 signaling involves hundreds of genes [31,32], we used an
expressional score calculated from the expression of five marker
genes (see Figure 1D and Methods). This score allowed us to
designate cell lines as high expressors (STAT1
H) and low expressors
(STAT1
L) of the IFN/STAT1 pathway. The combination of these
approaches allowed us to screen a panel of 55 cell lines
representing three sequential passages of B16F1 through
C57BL/6 mice (Table S1). We were then able to identify
relationships between expression levels of the IFN/STAT1
pathway, resistance of tumor clones to cytotoxic agents, and the
ability of tumor clones to colonize lungs.
A striking observation was that after only the first passage (P1),
established cell lines obtained from the lung colonies clearly
segregated into the STAT1
H and STAT1
L genotypes (Figure 1D).
Furthermore, STAT1
H clones demonstrated a 10-fold increase in
their ability to colonize the lungs compared to STAT1
L clones
(Figure 2). These results were further confirmed by propagation
of STAT1
H clones in the P2 and P3 in vivo passages demonstrating
both increased frequency of STAT1
H clones and an increase in the
level of IFN/STAT1 pathway up-regulation. In parallel, in each
passage the ratio of STAT1
H to STAT1
L clones increased. In the
P1 passage we observed only 2.161.2 colonies per mouse, while in
the P3 passage we observed an almost 20-fold increase in lung
colonization (37.9618.7 colonies per mouse; Figures 1 and 3).
These results demonstrate that tumor clones with increased
expression of the IFN/STAT1 pathway possess an aggressive
phenotype with an enhanced ability to colonize the lungs.
Previously, Fidler and Kripke demonstrated that some mono-
clones of B16F1 have preexistent abilities to aggressively colonize
the lungs [39]. We used a similar approach but focused on
expression of the IFN/STAT1 pathway (Figure 4A). We
concluded that the population of B16F1 cells contains preexisting
STAT1
H variants prior to in vivo passage. According to our prior
and current observations, these cells are resistant to cytotoxic and
genotoxic stress, are selected by the lung microenvironment, and
are more proficient at colonizing the lungs. Our results suggest
that a STAT1
H status is at least in part responsible for the
preexistent ability of B16F1 cells to colonize the lungs.
Additionally, we propose that significant up-regulation of the
IFN/STAT1 pathway in vivo likely creates a negative selection
pressure against STAT1
L clones that are not resistant to the
cytotoxic effects of this pathway, thereby selecting for STAT1
H
clones (Figure 4B). Importantly, our co-culture data suggest that
the lung microenvironment likely plays a significant role in this
selection (see [49,51,53]).
We tested the resistance of STAT1
H and STAT1
L cell lines and
tumors to IFNc, IR, and Dox (Figures 5–7). STAT1
H clones were
resistant to all treatments while STAT1
L clones were sensitive. This
is consistent with our previous data obtained with human head
and neck cell lines SCC61 and nu61 [17,18,25,44]. Fryknas et al
[22] showed that overexpression of the IFN/STAT1 pathway in
myeloma cell lines is associated with cross-resistance to IR and
Dox. Recent observations from our laboratory indicate that
resistance to STAT1 is also associated with resistance to the death
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the control of tumor development [44]. Therefore, it is reasonable
to propose that once tumor cells of different types acquire
resistance to the IFN/STAT1 pathway and are then selected
based on this resistance, they are also intrinsically resistant to a
wide variety of cytotoxic and genotoxic insults.
Finally, to provide mechanistic evidence of the dependence of
STAT1 on the observed aggressive STAT1
H genotype, we
generated stable STAT1 knockdowns in the P2M5A cell line,
which was the highest overexpressor of STAT1
H in the P2 passage
(Figure 3). STAT1 knockdown completely reversed the tumor
phenotype, significantly reducing lung colonization while signifi-
cantly increasing sensitivity to Dox (Figure 8). These results are
consistent with our previous report, in which stable knockdown of
STAT1 in nu61 (STAT1
H genotype) led to radiosensitization both
in vitro and in vivo [18]. Fryknas et al [22] reported similar effects
when inhibiting STAT1 in myeloma cell lines by fludarabine with
sensitization to both IR and Dox. Most recently Hui et al [24]
found overexpression of STAT1 in renal cell carcinoma relative to
normal kidney cells and were subsequently able to radiosensitize
tumor cells in vitro by suppressing STAT1 using siRNA or
fludarabine. Taken together with our current results these data
suggest that STAT1 is tightly associated with resistance to
genotoxic stress and provides a promising target for radio-and
chemo-sensitization of primary tumors and perhaps distant
metastasis.
The observation that constitutive overexpression of the IFN/
STAT1 pathway confers aggressive and therapy resistant tumor
clones leaves several unanswered questions which need to be
explored including the mechanisms by which activation of the
IFN/STAT1 pathway switches the pathway from ‘‘cytotoxic’’ to
‘‘pro-survival’’ and the mechanisms that underlie this switch.
Recently, we reported that constitutive overexpression of the
STAT1 pathway is associated with suppression of caspases 8, 9,
and 3 and therefore with suppression of the apoptotic response in
radiation and interferon resistant tumor cells [44]. In the current
report we also demonstrated that STAT1
H clones have an
impaired apoptotic response compared to STAT1
L clones
(Figure 8). Taken together these results suggest that resistance
to the IFN/STAT1 pathway is associated with impaired apoptosis.
Our findings suggest that once cells become resistant to apoptosis
they can survive activation of the pro-apoptotic branch of the
IFN/STAT1 pathway [54]. Still, we cannot exclude that a
mechanisms other than apoptosis may also lead to IFN/STAT1
pathway resistance [55–57].
In a previous study we also suggested that due to the complexity
of the network of STAT1-dependent genes, suppression of the
cytotoxic branch of IFN/STAT1 pathway [44] may reveal
STAT1-dependent genes with radioprotective and pro-survival
functions [18]. Indeed, STAT1 has been reported to control pro-
survival genes such as MCL1 [58], IFITM1 or Leu-13 [59],
multidrug resistance vault proteins [60], and USP18 (UBP43),
which mediate protection from IFN-induced cytotoxicity [61].
Importantly, we previously reported that MCL1, IFITM1, and
USP18 are co-expressed with STAT1 in the IR- and IFN-resistant
nu61 tumor [17]. We believe that systematic profiling of STAT1
knockdowns combined with biological validation will reveal the
essential and potentially oncogenic genes controlled by STAT1.
Overall our current data demonstrate that B16F1 syngeneic
model of lung metastasis supports our hypothesis that the
overexpression of the IFN/STAT1 pathway is an important
mediator in the development of an aggressive lung colonizing
phenotype that is resistant to negative selection pressures from the
lung microenvironment and concurrently resistant to conventional
cancer therapy including IR and chemotherapy. Future experi-
ments are needed to elucidate the mechanistic functions of STAT1
that confer this aggressive and therapy-resistant phenotype.
Recent reports and our current observations strongly suggest that
STAT1 provides a promising target for sensitization of primary
tumors and perhaps distant metastasis to anti-tumor therapy.
Methods
Cell culture
B16F1 and B16F10 murine melanoma cell lines were obtained
from the American Type Culture Collection (Manassas, VA) and
were cultured in RPMI 1640 media (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA), 100 U/mL penicillin, and 100 mg/mL
streptomycin (Invitrogen, Carlsbad, CA). Parental B16F1 cell lines
and daughter cell lines, obtained after in vivo passages, were
maintained in culture with the same media with 5% CO2 at 37uC
or stored in liquid nitrogen. For generation of STAT1 knockdowns
we used commercial shRNA constructs (Sigma, Saint Louis, MI),
as described elsewhere [18]. Cells were cultured the same as
parental B16F1 with the addition of 1 mg/ml of puromycin.
Mice
C57BL/6-Ncr mice were obtained from FCRI-Taconic (Ger-
mantown, NY) and B6.129S7-IFNc
tm1Ts2/2 (IFNc-null pheno-
type) were obtained from Jackson Laboratories (Bar Harbour,
ME). Animals were 5–7 weeks of age at the beginning of all
experiments. The care and treatment of experimental animals was
in accordance with institutional guidelines at the University of
Chicago.
Tumor cell injections
C57BL/6 mice were injected i.v. via the internal jugular (IJ)
vein or tail vein with tumor cells. For the IJ injections mice were
anesthetized with a Ketamine mixture. After shaving the neck/
clavicular area, the skin was incised and vein dissected free. 100
mL of cellular suspension was delivered under direct visualization
and without spillage. Cyanoacrilate was used for skin closure.
5610
4 tumor cells were injected i.v. per mouse.
Selection of cell lines from IFN/STAT1-expressing tumor
colonies
We followed the model of experiments from Fidler and
colleagues [26] with the addition of screening established cell
lines for expression of IFN/STAT1 pathway genes. Parental
B16F1 cell lines were injected in C57BL/6 mice and lung colonies
were harvested using gross dissection techniques. Each colony was
divided with one half used for QRT-PCR profiling and the other
half used for establishment of the primary cell lines (P1 panel).
QRT-PCR profiling of the P1 panel IFN/STAT1 pathway is
described in Methods Section 6. STAT1
H (high expressors) and
STAT1
L (low expressors) P1 cell lines were separately pooled and
injected into the next group of mice to generate the P2 panel of
cell lines. To represent progeny of P1 STAT1
H and P1 STAT1
L cell
lines the P2 cell lines were designated as P2
H and P2
L, respectively.
Finally, P2
H cell lines were pooled and passed in vivo as described
above to generate a P3
H panel of cell lines (See Figure S2 for a
schematic representation).
Collection of cell lines and in vivo samples
One-half of each lung colony was placed into an Eppendorf
tube, snap-frozen in liquid nitrogen, and transferred to a 280uC
STAT1 Mediates Metastases
PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e5821freezer. The other half of each sample was used to establish an
independent cell line. To accomplish this the lung colony fragment
was placed into a single well of a 24-well plate, covered by 1 ml of
culture media (see Methods section 1), and incubated in 5% CO2
at 37uC until a monolayer of cells, morphologically similar to
B16F1, was apparent under microscopic observation. The lung
colony fragment was removed, the cells were detached by
trypsinization, and then the cells were transferred to parallel 24-
well plates and cultured for 2-4 days. Cell cultures that produced a
consistent confluent monolayer were collected, frozen, and used in
the subsequent experiments. All established cell lines were stored
in liquid nitrogen.
IFN/STAT1 pathway scoring system based on QRT-PCR
profiling
To quantify IFN/STAT1 pathway expression levels in multiple
samples using QRT-PCR, we used a five gene marker set (STAT1,
IFIT1, IFIT3, IFITM1, and MX1) (see [18]). Primers for the
mouse marker genes are presented in Table S3. The QRT-PCR
technique used in these experiments is previously described [62].
For calculation of the IFN/STAT1 pathway expression score (ES)
we used the equation ES ~
Pn
i~1 Gi
    
n, where Gi=log2R,
R=fold ratio relative to B16F1, and n=number of genes.
Resistance to IFNc
Cell lines were plated in 96–well plates (5610
3 cells/well) and
treated with 10 ng/ml of murine IFNc (R&D Systems,
Minneapolis, MN). 48 hours later cell survival was determined
using the Promega CellTiter 96* Nonradioactive Cell Proliferation
Assay (MTT) (Promega, Madison, WI) according to the manu-
facturer’s instructions. Viability was calculated relative to a B16F1
control.
Resistance to ionizing radiation
In vivo radioresistance of STAT1
H and STAT1
L cell lines was
determined as previously described [42]. Briefly, B16F1, P2M3C
(STAT1
H), and P2M6B (STAT1
L) were injected subcutaneously
(1610
7 cells in 100 ml PBS) into the right hind limb of C57BL/6
mice. Five to seven days after injection the tumor volume was
150–200 mm
3. At the initiation of treatment (day 0) animals were
divided into appropriate treatment groups and randomized with
respect to the tumor size. A single dose of 20 Gy was delivered
using a Phillips orthovoltage X-ray generator operating at 250 kV
15 mA. Tumor volume was determined by direct measurement
with calipers and calculated by the formula (length6width6
depth/2 [42]. At the conclusion of each experiment animals were
euthanized using CO2 followed by cervical dislocation in
accordance with the institutional guidelines.
Sensitivity to Doxorubicin and apoptosis measurement
To test the effects of IFN/STAT1 pathway expression levels on
the apoptotic response to Dox we used three STAT1
H cell lines
(P3m2a, P2m3c, P3m5a) and three STAT1
L cell lines (P2m3,
P2m6b, and P2m5b). We selected one STAT1
H cell line (P2m5a)
and generated STAT1 knockdowns (see above) that were also
tested for Dox sensitivity. Cells were plated at a density of 5610
3
cells per well in 96-well plates in triplicates for 24 hours and then
treated with 1.0 mM Dox for 24 hours. Apoptosis was measured
using the Promega Caspase-Glo 3/7 assay (Madison, WI).
Luminescence was measured 30 minutes after addition of the
Caspase-Glo reagent using a TD-20/20 Luminometer. Signal
intensities for treated samples were background (no cells)
subtracted and divided by the intensity of an untreated control
to calculate relative induction of apoptosis.
Co-culture of B16F1 with C57BL/6 lung tissue
B16F1 cells were plated in triplicate at a density of 1610
6 per
well in a 6-well plate and incubated for 24 hours. 0.4 mm
polyester membrane transwell inserts (Costar 3450, Corning,
NY) were placed on top of each well and 1610
6 B16F1 cells
(mono-culture) or lung tissue removed from C57BL/6 mice that
was rinsed with warm PBS (co-culture) were added. B16F1 cells
on the bottom of the wells were removed after 8 and 24 hours of
mono- or co-cultured incubation. Expression of the IFN/STAT1
pathway was measured relative to B16F1 monoculture as
described above.
Detection of pre-existing STAT1
H clones
B16F1 cells were plated at 1 cell/well (monoclones) in a 96-well
plate (Nunclon Surface, Denmark). After one week of growth,
colonies were transferred to 24-well plates and grown to
confluence. 20 monoclone cultures were collected using Trizol
reagent and analyzed using QRT-PCR. Scoring and quantitative
estimation of the data are described above.
Supporting Information
Figure S1 Correlation between gene array expression levels and
QRT-PCR expression levels. Marker genes used for IFN/STAT1
expression score are labeled. Dashed line = 95% confidence
interval.
Found at: doi:10.1371/journal.pone.0005821.s001 (0.19 MB PPT)
Figure S2 Schematic representation of B16 P1, P2H, P2L, and
P3H passages. Note that steps within circle were repeated for each
passage to characterize lung colonies using QRT-PCR for IFN/
STAT1 pathway expression scores and to develop stable cell lines
in vitro.
Found at: doi:10.1371/journal.pone.0005821.s002 (0.20 MB PPT)
Table S1 STAT1 individual marker gene QRT-PCR levels and
overall IFN/STAT1 pathway expression score for all cell lines
relative to B16F1.
Found at: doi:10.1371/journal.pone.0005821.s003 (0.12 MB
DOC)
Table S2 IFNI ˆ3 resistance and STAT1 expression score for cell
lines tested.
Found at: doi:10.1371/journal.pone.0005821.s004 (0.03 MB
DOC)
Table S3 IFN/STAT1 marker gene QRT-PCR primers
Found at: doi:10.1371/journal.pone.0005821.s005 (0.03 MB
DOC)
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